Based on clinical experience, which type of cancers have the best response rate to AVEMAR treatment?
As is indicated in the instructions accompanying Avemar, its known beneficial effects and lack of toxic side effects renders the application of Avemar both possible and permissable for all types of tumors. Naturally, we have the most experience with diseases in which Avemar was used in the frame of clinical trials, namely gastrointestinal cancers (especially colorectal cancer), squamous cell carcinoma of the oral cavity and malignant melanomas. We also have somewhat less, but nevertheless sufficient, evidence regarding the treatment of bladder and renal cancer, cancer of the pharynx/larynx, cancer of the salivary glands, liver cancer and breast cancer for those cases where objective methods could be used to establish the Avemar’s effectiveness. Never-theless, it is important to emphasize that we never replaced standard therapies with Avemar, the therapy was always left unchanged and Avemar was used only as supplementary treatment. This must be taken into account when considering report
